Stocks
Fractyl Health, Inc.GUTS
NASDAQHealthcareBiotechnology$1.36
Price as of · delayed, not real-time
A clinical-stage metabolic therapeutics company developing treatments for obesity and type 2 diabetes, with a lead candidate targeting the duodenum to restore metabolic function. Its pipeline includes a novel, minimally invasive procedure and an injectable GLP-1-based therapy, positioning it in the competitive obesity drug market. Investors track GUTS for its differentiated approach and early clinical data.
52W Range: $1.33-$29.34
Congressional Interest in Fractyl Health, Inc. (GUTS)
No congressional trades have been disclosed for Fractyl Health, Inc. (GUTS) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading GUTS?
No congressional trades found for this stock.